Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms

This is a single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric and adolescent subjects (aged between 6 months and \<18 years, ≥6 kg body weight \[BW\]) with mature B-cell neoplasms and aggressive lymphomas that relapsed after or are refractory to one or more prior therapies, including subjects with primary refractory disease.

Trial Details

NCT ID
NCT06508931
Phase
PHASE2
Sponsor
Miltenyi Biomedicine GmbH
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • zamtocabtagene autoleucel (MB-CART2019.1)
Locations (sample)
  • Paris, Boulevard Sérurier 48, France|48.85341,2.3488
  • Villejuif, France|48.7939,2.35992
  • Münster, Albert-Schweitzer-Campus 1, Gebaeude A1, Germany|51.96236,7.62571
  • Rome, Piazza Sant Onofrio 4, Italy|41.89193,12.51133
  • Utrecht, Heidelberglaan 25, Netherlands|52.09083,5.12222

Key Eligibility Criteria

  • Is able to provide age-appropriate assent/consent (as applicable, according to local legislation) and/or have a guardian able to provide consent si…
  • Has histologically confirmed mature CD19+ and/or CD20+ B-cell neoplasm such as:
  • Burkitt lymphoma/Burkitt leukemia
  • Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →